Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

3902 - Enhancer of zest homolog 2 (EZH2) expression in well and moderately differentiated pancreatic neuroendocrine tumor (pNET)


08 Oct 2016


Poster Display


Riccardo Marconcini


Annals of Oncology (2016) 27 (6): 136-148. 10.1093/annonc/mdw369


R. Marconcini1, P. Faviana2, D. Campani2, L. Galli1, A. Antonuzzo3, C. Orlandini1, A. Falcone1, S. Ricci3

Author affiliations

  • 1 U.o. Oncologia Medica 2 Universitaria, Azienda Ospedaliera Universitaria S.Chiara, 56100 - Pisa/IT
  • 2 U.o. Anatomia Patologica, Azienda Ospedaliera Cisanello Pisa, Pisa/IT
  • 3 U.o. Oncologia Medica 1 Ospedaliera, Azienda Ospedaliera Universitaria S.Chiara, 56100 - Pisa/IT


Abstract 3902


Enhancer of zest homolog 2 (EZH2) is the catalytic subunit of polycomb repressive complex 2 with histone H3 methyltransferase function. EZH2 has been shown to be over-expressed in several malignant neoplasms and to be associated with aggressive behavior. Few data are currently available for NETs. EZH2 represents a potential therapeutic target and EZH2 inhibitor drugs are in development. In this study, we evaluated EZH2 expression in well differentiated G1 (Ki67


Immunohistochemical analyzes for nuclear EZH2 expression were performed using a commercially available detection kit on removed primary tumor tissue. We assessed the percentage of positive tumor cells. we considered negative score if expression was positive in less than 10% cells. We used the Chi Square test to compare the expression of EZH2 in the different groups. Histopathological data and clinical data pNET were also collected.


Thirty patients with pNET have been assessed (9 G1 and 21 G2 pNET). Eleven patients had metachronous metastases at median time of 49 (15-114) months, 8 patients had synchronous metastases and 11 patients had primary tumor radically removed without recurrence of disease. EZH2 was overexpressed in both G1 and G2 pNET: we found no significant difference of EZH2 expression between G1 and G2 pNET. In metastatic patients, negative score (


EZH2 is expressed in pNET. Data show a statistically significant difference in the expression of EZH2 between groups with metachronous metastases (more indolent clinical course), and the group with synchronous metastases (more aggressive clinical course), with lower expression in the first group. This data could be interesting in terms of therapeutic strategy. Further analisis are currently in progress in a larger group of NET patients. Investigation of EZH2 inhibitor drugs in pNET appear feasible

Clinical trial identification

Legal entity responsible for the study

Azienda Ospedaliera Universitaria Pisana


Foundation Aprio


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings